AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16081626 — intervention group
Group type: COMPARATOR
Intervention: Deficit group (DEF) - energy not replaced during exercise
Number of subjects: 16
Study 12151999 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg efavirenz
Number of subjects: 12
Study 12151999 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg efavirenz
Number of subjects: 12
Study 12151999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10630345 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnoanesthesia (HYP)
Number of subjects: 318
Study 10630345 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 318
Study 7549287 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula enriched with omega-6 and omega-3 long-chain polyunsaturated fatty acids (LCP-F)
Number of subjects: 22
Study 7549287 — intervention group
Group type: COMPARATOR
Intervention: Conventional infant formula without long-chain polyunsaturated fatty acids (F)
Number of subjects: 22
Study 2184794 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (100 to 400 mg twice a day over a 6-week period)
Number of subjects: 133
Study 2184794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 7259078 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin-halothane
Number of subjects: 187
Study 7259078 — intervention group
Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 187
Study 7259078 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 187
Study 30987667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang (SDT) 3 g three times daily for 8 weeks
Number of subjects: 60
Study 30987667 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 g three times daily for 8 weeks
Number of subjects: 60
Study 30987667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang (SDT)
Number of subjects: 60
Study 30987667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27893018 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 PUFAs (1.4 g daily) plus CBCM
Number of subjects: 304
Study 27893018 — intervention group
Group type: COMPARATOR
Intervention: Placebo (paraffin oil) plus CBCM
Number of subjects: 304
Study 26448436 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-out container provided during meal
Number of subjects: 50
Study 26448436 — intervention group
Group type: COMPARATOR
Intervention: No take-out container provided (Control)
Number of subjects: 50
Study 23577663 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation (Mini-HLM)
Number of subjects: 120
Study 23577663 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 120
Study 21279664 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure with small stitches (5-8 mm from wound edge, less than 5 mm apart)
Number of subjects: 691
Study 21279664 — intervention group
Group type: COMPARATOR
Intervention: Closure with large stitches (more than 1 cm from wound edge)
Number of subjects: 691
Study 18813219 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (0.5 mg dutasteride + 0.4 mg tamsulosin once daily)
Number of subjects: 325
Study 18813219 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride (0.5 mg once daily)
Number of subjects: 325
Study 18813219 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg once daily)
Number of subjects: 325
Study 18813219 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 325
Study 17499445 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal alcohol feedback intervention
Number of subjects: 177
Study 17499445 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 177
Study 15501790 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg of Vi-rEPA
Number of subjects: 46
Study 15501790 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 microg of Vi-rEPA
Number of subjects: 46
Study 15501790 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg of Vi-rEPA
Number of subjects: 46
Study 15501790 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-rEPA (all dosages)
Number of subjects: 46
Study 11494441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (15 ml/day for 28 days)
Number of subjects: 42
Study 11494441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 9610787 — intervention group
Group type: COMPARATOR
Intervention: BB genotype
Number of subjects: 372
Study 9610787 — intervention group
Group type: COMPARATOR
Intervention: Bb genotype
Number of subjects: 372
Study 7740377 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifater
Number of subjects: 106
Study 7740377 — intervention group
Group type: COMPARATOR
Intervention: 4-drug regimen (isoniazid, rifampicin, pyrazinamide, ethambutol)
Number of subjects: 106
Study 7740377 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 106
Study 3179149 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 5 mg i.v.
Number of subjects: 42
Study 3179149 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 10 mg i.v.
Number of subjects: 42
Study 3179149 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 15 mg i.v.
Number of subjects: 42
Study 3179149 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanalgesia
Number of subjects: 42
Study 3179149 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane or enflurane anaesthesia
Number of subjects: 42
Study 31499249 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral viscous budesonide (OVB)
Number of subjects: 58
Study 31499249 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone from a multidose inhaler (MDI)
Number of subjects: 58
Study 30635130 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine (H3 receptor inverse agonist)
Number of subjects: 0
Study 30635130 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioperamide (H3 receptor inverse agonist)
Number of subjects: 0
Study 30635130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27993947 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of 10-year CHD risk based on conventional risk factors and genetic risk score (n=104)
Number of subjects: 207
Study 27993947 — intervention group
Group type: COMPARATOR
Intervention: Conventional risk factors alone (n=103)
Number of subjects: 207
Study 26370444 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone coaching sessions (5 sessions of telephone-based counselling)
Number of subjects: 379
Study 26370444 — intervention group
Group type: COMPARATOR
Intervention: Standard support
Number of subjects: 379
Study 26370444 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone coaching sessions
Number of subjects: 379
Study 23421438 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure ventilation (NPV) during exercise training
Number of subjects: 36
Study 23421438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NPV)
Number of subjects: 36
Study 21504304 — intervention group
Group type: EXPERIMENTAL
Intervention: Distally tapered, extended coated stem
Number of subjects: 50
Study 21504304 — intervention group
Group type: COMPARATOR
Intervention: Straight, proximally coated stem
Number of subjects: 50
Study 19466229 — intervention group
Group type: EXPERIMENTAL
Intervention: APF gel application for 1 min
Number of subjects: 15
Study 19466229 — intervention group
Group type: EXPERIMENTAL
Intervention: APF gel application for 4 min
Number of subjects: 15
Study 19466229 — intervention group
Group type: COMPARATOR
Intervention: Not treated (control)
Number of subjects: 15
Study 16752874 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil (100 mcg)
Number of subjects: 79
Study 16752874 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil (400 mcg)
Number of subjects: 79
Study 16752874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 15223097 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg buprenorphine in 24 h
Number of subjects: 40
Study 15223097 — intervention group
Group type: COMPARATOR
Intervention: Conventional doses of buprenorphine tapered down over 5 days
Number of subjects: 40
Study 11330408 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 g of native amylomaize starch, containing 28 g of resistant starch type II
Number of subjects: 23
Study 11330408 — intervention group
Group type: COMPARATOR
Intervention: 45 g of maltodextrin (placebo)
Number of subjects: 23
Study 9400788 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (specific treatment not detailed)
Number of subjects: 454
Study 9400788 — intervention group
Group type: COMPARATOR
Intervention: Prednisone treatment group
Number of subjects: 454
Study 8387254 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 25 pmol/kg/min
Number of subjects: 8
Study 8387254 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion plus placebo inhalation
Number of subjects: 8
Study 8387254 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion plus albuterol inhalation (5 mg)
Number of subjects: 8
Study 8387254 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP infusion (both rates)
Number of subjects: 8
Study 8387254 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP infusion at 25 pmol/kg/min
Number of subjects: 8
Study 3318560 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% lidocaine carbonate
Number of subjects: 30
Study 3318560 — intervention group
Group type: COMPARATOR
Intervention: 1.0% lidocaine hydrochloride
Number of subjects: 30
Study 29937110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education by a student or pharmacist on how to read the label
Number of subjects: 92
Study 29937110 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tailored education)
Number of subjects: 92
Study 29937110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education
Number of subjects: 92
Study 27510396 — intervention group
Group type: COMPARATOR
Intervention: CPR with 100 compressions per minute (CPM)
Number of subjects: 470
Study 27510396 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR with 120 compressions per minute (CPM)
Number of subjects: 470
Study 27510396 — intervention group
Group type: COMPARATOR
Intervention: CPR with 100 CPM
Number of subjects: 470
Study 27510396 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR with 120 CPM
Number of subjects: 470
Study 25310117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-infant pair clinics
Number of subjects: 1230
Study 25310117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-infant pair clinics plus SMS reminders
Number of subjects: 1230
Study 25310117 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 1230
Study 22474993 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine for 2 weeks before ICSI
Number of subjects: 129
Study 22474993 — intervention group
Group type: COMPARATOR
Intervention: ICSI alone (control group)
Number of subjects: 129
Study 22474993 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine followed by ICSI
Number of subjects: 129
Study 21034597 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo
Number of subjects: 219
Study 21034597 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 219
Study 18397683 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 microg/day)
Number of subjects: 13
Study 18397683 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (1.5 microg/day)
Number of subjects: 13
Study 18397683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15851889 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg meperidine
Number of subjects: 45
Study 15851889 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg butorphanol
Number of subjects: 45
Study 15851889 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg meperidine plus 0.5 mg butorphanol
Number of subjects: 45
Study 15851889 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 12360366 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (0.625 mg/day conjugated equine estrogens combined with 2.5 mg/day medroxyprogesterone acetate)
Number of subjects: 10000
Study 12360366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10000
Study 10613728 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) treatment (3 x 10(6), 3 times a week, for 1 year) (n = 30)
Number of subjects: 58
Study 10613728 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment (n = 28)
Number of subjects: 58
Study 10613728 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) treatment
Number of subjects: 58
Study 9093726 — intervention group
Group type: EXPERIMENTAL
Intervention: 6S-LV (100 mg/sqm/i.v.) + 5-FU (370 mg/sqm/15 min i.v. infusion) for 5 days every 28 days (arm A)
Number of subjects: 422
Study 9093726 — intervention group
Group type: COMPARATOR
Intervention: 6S-LV (10 mg/sqm/i.v.) + 5-FU (doses as above) for 5 days every 28 days (arm B)
Number of subjects: 422
Study 9093726 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 422
Study 8239245 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 21
Study 8239245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3698513 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (NA) infusion for 3 hours
Number of subjects: 8
Study 3698513 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANG II) infusion for 3 hours
Number of subjects: 8
Study 3698513 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) infusion for 3 hours
Number of subjects: 8
Study 30541219 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic tracheal tube ventilation (group A)
Number of subjects: 28
Study 30541219 — intervention group
Group type: COMPARATOR
Intervention: Modified laryngeal mask airway (group B)
Number of subjects: 28
Study 29424513 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Misgav-Ladach
Number of subjects: 137
Study 29424513 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel-Kerr
Number of subjects: 137
Study 29424513 — intervention group
Group type: COMPARATOR
Intervention: Kerr-half infraumbilical
Number of subjects: 137
Study 24603562 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supplementing enteral Microlipid (ML) and fish oil (FO)
Number of subjects: 36
Study 24603562 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 36
Study 23016381 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw fixation (uni-PS) with minimally transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 102
Study 23016381 — intervention group
Group type: COMPARATOR
Intervention: Bilateral pedicle screw fixation (bi-PS) with posterior lumbar interbody fusion (PLIF)
Number of subjects: 102
Study 20546511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (Botulinum toxin A)
Number of subjects: 0
Study 20546511 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone and lidocaine (TA group)
Number of subjects: 0
Study 18537952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (initial dose 50 mg, adjustable to 25 or 100 mg)
Number of subjects: 108
Study 18537952 — intervention group
Group type: COMPARATOR
Intervention: Apomorphine (initial dose 2 mg, adjustable to 3 mg)
Number of subjects: 108
Study 18537952 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference after treatment
Number of subjects: 108
Study 16318959 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (2 mg or 8 mg tablets; maximum daily dose: 8 mg)
Number of subjects: 60
Study 16318959 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone (racemic R-/S-methadone)
Number of subjects: 60
Study 12556143 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg artemether, administered orally for a total of six doses once every 4 weeks
Number of subjects: 322
Study 12556143 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered orally for a total of six doses once every 4 weeks
Number of subjects: 322
Study 12556143 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg artemether
Number of subjects: 322
Study 12556143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 10659911 — intervention group
Group type: EXPERIMENTAL
Intervention: Estroprogestin (E/P) pill (gestroden 0.75 mg and ethynlestradiol 0.03 mg) for 12 months
Number of subjects: 102
Study 10659911 — intervention group
Group type: COMPARATOR
Intervention: Gonadotrophin releasing hormone agonist (GNRHa) (tryptorelin 3.75 mg slow release every 28 days for 4 months) followed by E/P pill for 8 months
Number of subjects: 102
Study 8968851 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (25% CHO, n = 31)
Number of subjects: 68
Study 8968851 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet (45% CHO, n = 37)
Number of subjects: 68
Study 30772697 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GBPen) at a fixed dose of 600 mg/day
Number of subjects: 0
Study 30772697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29869298 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg TQ Intermediate Aged
Number of subjects: 14
Study 29869298 — intervention group
Group type: COMPARATOR
Intervention: 300 mg TQ Control
Number of subjects: 14
Study 27534856 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg daily for 6 weeks
Number of subjects: 36
Study 27534856 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 36
Study 27534856 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg daily
Number of subjects: 36
Study 27534856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 27534856 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil and Placebo
Number of subjects: 36
Study 25099747 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic therapy (Group A)
Number of subjects: 40
Study 25099747 — intervention group
Group type: COMPARATOR
Intervention: No symbiotic therapy (Group B)
Number of subjects: 40
Study 22057309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 μg/kg before induction, additional 50-μg boluses during anesthesia
Number of subjects: 84
Study 22057309 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 μg/kg infused in 10 min before induction, 0.1 μg/kg/min during anesthesia
Number of subjects: 84
Study 22057309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg infused in 10 min before induction, 1 μg/kg/h during anesthesia
Number of subjects: 84
Study 18668472 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 63
Study 18668472 — intervention group
Group type: COMPARATOR
Intervention: White Light Imaging
Number of subjects: 63
Study 17285817 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 60
Study 17285817 — intervention group
Group type: COMPARATOR
Intervention: Chloral hydrate
Number of subjects: 60
Study 14639668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 10
Study 14639668 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 10
Study 11078175 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg twice daily for 3 weeks
Number of subjects: 0
Study 11078175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9187896 — intervention group
Group type: EXPERIMENTAL
Intervention: Goretex sling
Number of subjects: 48
Study 9187896 — intervention group
Group type: COMPARATOR
Intervention: Indigenous material graft (rectal fascia)
Number of subjects: 48
Study 1396493 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic desensitization by clinical psychologists
Number of subjects: 72
Study 1396493 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic desensitization by clinical oncologists
Number of subjects: 72
Study 1396493 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic desensitization by oncology nurses
Number of subjects: 72
Study 1396493 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 72
Study 2412002 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran at 1 g/kg wt/24 hr for 5 days in addition to standard resuscitation and treatment
Number of subjects: 28
Study 2412002 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 28
Study 29343142 — intervention group
Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA, 500 U/2 mL dilution
Number of subjects: 134
Study 29343142 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 134
Study 27441684 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (MEI)
Number of subjects: 334
Study 27441684 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (without MEI)
Number of subjects: 334
Study 23892190 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside-in (Aris® transobturator sling system)
Number of subjects: 66
Study 23892190 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside-out (TVT™-O)
Number of subjects: 66
Study 23892190 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 66
Study 22270202 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyconate suture
Number of subjects: 48
Study 22270202 — intervention group
Group type: COMPARATOR
Intervention: Poliglecaprone 25 suture
Number of subjects: 48
Study 21041593 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevention program (group behavioral counseling to promote healthy eating and increased physical activity)
Number of subjects: 303
Study 21041593 — intervention group
Group type: COMPARATOR
Intervention: Alternative intervention (self-esteem and social efficacy)
Number of subjects: 303
Study 21041593 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevention program
Number of subjects: 303